A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteers

References

• Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933–989.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–1847.
   PubMed Web of Science ®Google Scholar
• Cook C, Cole G, Asaria P, et al. The annual global economic burden of heart failure. Int J Cardiol. 2014;171:368–376.
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–1658.
   PubMed Web of Science ®Google Scholar
• MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353(9169):2001–2007.
   PubMed Web of Science ®Google Scholar
• McMurray JJ. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure. Eur J Heart Fail. 2011;13(9):929–936.
   PubMed Web of Science ®Google Scholar
• Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol. 2014;176(3):630–639.
   PubMed Web of Science ®Google Scholar
• Mangiafico S, Costello-Boerrigter LC, Andersen IA, et al. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013;34(12):886–893.
   PubMed Web of Science ®Google Scholar
• Langenickel TH, Dole WP. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure. Drug Discov Today. 2012;9(4):e131–9.
   Google Scholar
• Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2(6):663–670.
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula S, Langenickel T, Pal P, et al. Clinical pharmacokinetics of sacubitril/valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor. Clin Pharmacokinet. 2017;56(12):1461–1478.
   PubMed Web of Science ®Google Scholar
• Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401–414.
   PubMed Web of Science ®Google Scholar
• Shi J, Wang X, Nguyen J, et al. Sacubitril is selectively activated by carboxylesterase 1 (CES1) in the liver and the activation is affected by CES1 genetic variation. Drug Metab Dispos. 2016;44(4):554–559.
   PubMed Web of Science ®Google Scholar
• Campbell DJ. Long-term neprilysin inhibition - implications for ARNIs. Nat Rev Cardiol. 2017;14(3):171–186.
   PubMed Web of Science ®Google Scholar
• ENTRESTO (sacubitril/valsartan) Tablets. CENTER FOR DRUG EVALUATION AND RESEARCH. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000PharmR.pdf
   Google Scholar
• Ye L, Wang J, Chen Q, et al. LCZ696, a promising novel agent in treating hypertension (a meta-analysis of randomized controlled trials). Oncotarget. 2017;8(64):107991–108005.
   PubMedGoogle Scholar
• Williams B, Cockcroft JR, Kario K, et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study. Hypertension. 2017;69(3):411–420.
   PubMed Web of Science ®Google Scholar
• Li Q, Li L, Wang F, et al. Effect and safety of LCZ696 in the treatment of hypertension. Meta-Anal Med (Baltimore). 2019 Jul;98(28):e16093.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68(13):1476–1488.
   PubMed Web of Science ®Google Scholar
• Choi DH, Li C, Choi JS. Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin. J Pharm Pharmacol. 2010;62:908–914.
   PubMed Web of Science ®Google Scholar
• Sachinidis A, Ko Y, Weisser P, et al. EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells. J Hypertens. 1993;11(2):155–162.
   PubMed Web of Science ®Google Scholar
• Yang SH, Cho YA, Choi JS. Effects of ticlopidine on pharmacokinetics of losartan and its main metabolite EXP-3174 in rats. Acta Pharmacol Sin. 2011a;32:967–972.
   PubMed Web of Science ®Google Scholar
• Liu AC, Zhao LX, Xing J, et al. Pre-treatment with curcumin enhances plasma concentrations of losartan and its metabolite EXP3174 in rats. Biol Pharm Bull. 2012;35:145–150.
   PubMed Web of Science ®Google Scholar
• Sun JC, Xu WJ, Hua H, et al. Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor. Biomed Pharmacother. 2020;19(129):110410.
   Google Scholar
• Kario SN, Chiang FT, Supasyndh O, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698–705.
   PubMed Web of Science ®Google Scholar
• Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Cited 2008 Mar 2. Available from: <https://www.fda.gov/downloads/drugs/guidances/ucm078932.pdf>Cited(2005)
   Google Scholar
• Hedner T, Oparil S, Rasmussen K, et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens. 1999;12(4 Pt 1):414–417.
   PubMed Web of Science ®Google Scholar
• Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(5):283–291.
   PubMedGoogle Scholar
• Han Y, Ayalasomayajula S, Pan W, et al. Pharmacokinetics, safety and tolerability of sacubitril/valsartan (LCZ696) after single-dose administration in healthy Chinese subjects. Eur J Drug Metab Pharmacokinet. 2017;42(1):109–116.
   PubMed Web of Science ®Google Scholar
• Miners JS, Barua N, Kehoe PG, et al. Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol. 2011;70(11):944–959.
   PubMed Web of Science ®Google Scholar
• Langenickel TH, Tsubouchi C, Ayalasomayajula S, et al. The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol. 2016;81(5):878–890.
   PubMed Web of Science ®Google Scholar